Memantine Augmentation Improves Symptoms in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder: A Randomized Controlled Trial

Abstract

Introduction There is a large body of evidence on the clinical benefits of augmentation therapy with glutamate-modulating agents, such as memantine in reducing OCD symptoms.

Methods A double-blind, placebo-controlled trial was conducted on SRIrefractory OCD patients. Thirty-two patients were randomized to receive either 20 mg/day memantine or placebo augmentation and were visited at baseline and every 4 weeks for 12 weeks. Results were measured using the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS).

Results The Y-BOCS total score was significantly reduced in the memantine group at the end of weeks 8 and 12, while no improvement was observed in the placebo group throughout the trial. A reduction of 40.9% in the mean Y-BOCS total score by week 12 in the memantine group resulted in 73.3% of patients achieving treatment response. The findings showed that a time to effect of 8 weeks was necessary to observe significant improvement in OCD symptoms, while treatment response was only seen after 12 weeks of memantine augmentation.

Discussion Memantine is an effective and well-tolerated augmentation in severe OCD patients refractory to SRI monotherapy.

• References

• 1 Pittenger C, Kelmendi B, Bloch M. et al. Clinical treatment of obsessive compulsive disorder. Psychiatry (Edgmont) 2005; 2: 34-43
• 2 Bruno A, Pandolfo G, Cedro C. et al. Effect of ziprasidone augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: A 12-week, open-label uncontrolled preliminary study. Clin Neuropharmacol 2016; 39: 6-9
• 3 Koran LM, Hanna GL, Hollander E. et al. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry 2007; 164: 5-53
• 4 Kellner M. Drug treatment of obsessive-compulsive disorder. Dialogues Clin Neurosci 2010; 12: 187-197
• 5 Mohammadi MR, Ghanizadeh A, Rahgozar M. et al. Prevalence of obsessive-compulsive disorder in Iran. BMC Psychiatry 2004; 4: 2
• 6 Pallanti S, Hollander E, Bienstock C. et al. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002; 5: 181-191
• 7 Atmaca M. Treatment-refractory obsessive compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2016; 70: 127-133
• 8 Akyol Ardic U, Ercan ES, Kutlu A et al. Successful treatment response with aripiprazole augmentation of SSRIs in refractory obsessive-compulsive disorder in childhood. Child Psychiatry Hum Dev 2016 [Epub ahead of print]
• 9 Veale D, Miles S, Smallcombe N. et al. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. BMC Psychiatry 2014; 14: 317
• 10 Aouizerate B, Guehl D, Cuny E. et al. Pathophysiology of obsessive-compulsive disorder: A necessary link between phenomenology, neuropsychology, imagery and physiology. Prog Neurobiol 2004; 72: 195-221
• 11 Albelda N, Bar-On N, Joel D. The role of NMDA receptors in the signal attenuation rat model of obsessive-compulsive disorder. Psychopharmacology (Berl) 2010; 210: 13-24
• 12 Zdanys K, Tampi RR. A systematic review of off-label uses of memantine for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1362-1374
• 13 Arnold PD, Rosenberg DR, Mundo E. et al. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl) 2004; 174: 530-538
• 14 Paydary K, Akamaloo A, Ahmadipour A. et al. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther. 2016; 41: 214-219
• 15 Coric V, Taskiran S, Pittenger C. et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial. Biol Psychiatry 2005; 58: 424-428
• 16 Afshar H, Roohafza H, Mohammad-Beigi H. et al. N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2012; 32: 797-803
• 17 Bloch MH, Wasylink S, Landeros-Weisenberger A. et al. Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry 2012; 72: 964-970
• 18 Stryjer R, Budnik D, Ebert T. et al. Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs-an open-label study. Clin Neuropharmacol 2014; 37: 79-81
• 19 Lafleur DL, Pittenger C, Kelmendi B. et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl) 2006; 184: 254-256
• 20 Ferguson JM, Shingleton RN. An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol 2007; 30: 136-144
• 21 Keck Jr. PE, Hsu HA, Papadakis K. et al. Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: A pilot evaluation. Clin Neuropharmacol 2009; 32: 199-204
• 22 Amidfar M, Khiabany M, Kohi A. et al. Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: Randomized, double-blind, placebo-controlled study. J Clin Pharm Ther 2017; 42: 44-50
• 23 Wu K, Hanna GL, Rosenberg DR. et al. The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacol Biochem Behav 2012; 100: 726-735
• 24 Haghighi M, Jahangard L, Mohammad-Beigi H. et al. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology (Berl) 2013; 228: 633-640
• 25 Ghaleiha A, Entezari N, Modabbernia A. et al. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res 2013; 47: 175-180
• 26 Stewart SE, Jenike EA, Hezel DM. et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol 2010; 30: 34-39
• 27 Sahraian A, Jahromi LR, Ghanizadeh A. et al. Memantine as an adjuvant treatment for obsessive compulsive symptoms in manic phase of bipolar disorder: A randomized, double-blind, placebo-controlled Clinical Trial. J Clin Psychopharmacol 2017; 37: 246-249
• 28 Pasquini M, Biondi M. Memantine augmentation for refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1173-1175
• 29 Poyurovsky M, Weizman R, Weizman A. et al. Memantine for treatment-resistant OCD. Am J Psychiatry 2005; 162: 2191-2192
• 30 Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial. J Clin Psychopharmacol 2009; 29: 51-55
• 31 Feusner JD, Kerwin L, Saxena S. et al. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacol Bull 2009; 42: 81-93
• 32 Goodman WK, Price LH, Rasmussen SA. et al. The Yale-brown obsessive compulsive scale. II. validity. Arch Gen Psychiatry 1989; 46: 1012-1016
• 33 Goodman WK, Price LH, Rasmussen SA. et al. The Yale-brown obsessive compulsive scale. I. development, use, and reliability. Arch Gen Psychiatry 1989; 46: 1006-1011
• 34 Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 400-412
• 35 Jenike MA, Rauch SL. Managing the patient with treatment-resistant obsessive compulsive disorder: Current strategies. J Clin Psychiatry 1994; 55 (Suppl): 11-17